Seres Therapeutics, Inc. (MCRB)
After hours:
| Previous Close | 1.3600 |
| Open | 1.3800 |
| Bid | 1.3100 x 900 |
| Ask | 1.3400 x 900 |
| Day's Range | 1.2900 - 1.4299 |
| 52 Week Range | 0.5400 - 5.2900 |
| Volume | |
| Avg. Volume | 4,860,778 |
| Market Cap | 199.911M |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5900 |
| Earnings Date | Aug 06, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.45 |
Simply Wall St.Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years
Seres Therapeutics, Inc. ( NASDAQ:MCRB ) shareholders will doubtless be very grateful to see the share price up 125% in...
GlobeNewswireSeres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on June 5, 2024, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 6,188 shares of its common stock to one new employee, consisting of stock options to purchase 4,125 shares of common stock and restricted stock units (“RSUs”) covering 2,063 s
PR NewswireNestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its l
